Skip to main content

Posts tagged with "Diabetes and Obesity"

  • Business and Markets

    Exubera Spirals Toward the Drainpipe

    You know, you can run the biggest marketing behemoth the drug industry has ever seen – but if people really aren’t interested in buying your product (and if insurance companies really aren’t interested in paying for it), that’s not enough. The evidence? Pfizer’s Exubera, the inhaled insulin that for years was thought b… Read More
  • Clinical Trials

    Deactivation, After All

    Four years ago I wrote about an unusual Roche diabetes compound targeting glucokinase. The odd thing about it was that it made the enzyme more active, which is something you can only rarely hope to do. Enzymes generally run near the top of their specs, unless there’s some built-in switch that keeps them damped down… Read More
  • Biological News

    Visfatin: Real Or Not?

    A commentor to my Proteomics 101 post the other day brought up an important point: that before you can have a chance to figure out what a protein is doing, you have to know that it exists. Finding the darn things is no small job, since you’re digging through piles of chemically similar stuff to… Read More
  • Diabetes and Obesity

    Right Down the Alli

    If you’re wondering why Sanofi-Aventis would spend so much time and money on a tricky, problematic drug like rimonabant, just take a look at the reception of GSK’s over-the-counter version of Xenical (orlistat), brand-named Alli. What’s ridiculous about all the coverage and hype is that the drug isn’t (of course) new. And it… Read More
  • Clinical Trials

    Rimonabant: Down to Earth

    Everyone will have heard the news about Wednesday’s FDA Advisory Commitee vote on Accomplia / Zimulti (rimonabant). If you’d tried to convince folks a few years ago that this drug wouldn’t make it to a vote until summer of 2007, and would be unanimously rejected when it did, you’d have been looked at with pity… Read More
  • Cardiovascular Disease

    Rimonabant, Out In the Light

    The FDA briefing documents for Wednesday’s discussion of Accomplia / Zimulti (rimonabant) have been posted, and they’re an interesting read indeed. As everyone in the industry knows, this drug was once looked on as the next potential record-breaker, and writing the first part of this sentence in that verb form tells you a lot about… Read More
  • Cardiovascular Disease

    The Avandia Wars Continue

    GlaxoSmithKline is breaking out the data to respond to the Nissen and Wolski NEJM paper on the possible cardiovascular risks of Avandia (rosiglitazone). In a letter published by The Lancet (PDF), the company’s chief medical officer, Ronald Krall, defends the drug (and the company): “GlaxoSmithKline did similar meta-analyses in 2005 and… Read More
  • Cardiovascular Disease

    More Avandia, And More on Marketing

    Insider, author of the Pharmagossip site, sent along this link to an article on Avandia at the Health Care Renewal site, flagged as “essential reading”. After looking it over, I don’t think I agree, and I thought it might be worthwhile to explain why. The HCR piece quotes extensively from this New York Times article… Read More
  • Cardiovascular Disease

    Avandia: Trouble or Not?

    Steve Nissen has (once again) made waves with an analysis of cardiovascular risk. This time the subject is Avandia (rosiglitazone), a therapy for diabetes that’s the oldest PPAR-gamma drug on the market. A meta-analysis of 42 reported clinical trials of the drug led to the conclusion that rosiglitazone is associated with a statistically signi… Read More
  • Diabetes and Obesity

    Exubera: This Time With Feeling

    Looks like my doubts about the potential of Pfizer’s inhaled insulin Exubera were well-founded. Pfizer’s having some trouble making headway, and have announced a re-launch of the product. Needless to say, you don’t re-launch products that are performing up to expectation. When I wrote about the product a year or so ago, various di… Read More